AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01285310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
Trial: NCT04208620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously
Trial: NCT01603667
Drug: PG2
RxNorm normalized name: Fossaoprin SPG2 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days
Trial: NCT01603667
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5\~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days
Trial: NCT01268839
Drug: TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg tablet once daily for 28 days
Trial: NCT01268839
Drug: TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg tablet once daily for 14 days
Trial: NCT03186365
Drug: Zepatier Oral Product
RxNorm normalized name: Zepatier Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
Trial: NCT04260035
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 episodic migraine patients without aura of both genders are randomized to receive a 2-hour infusion of VIP and/or sterile saline on two days, with at least one week in between.
Trial: NCT00924053
Drug: EGT0001474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
Trial: NCT00924053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules to match EGT0001474
Trial: NCT01456260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
Trial: NCT01456260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
Trial: NCT01456260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
Trial: NCT00379158
Drug: Micronutrient supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03976934
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pills
Trial: NCT00355524
Drug: TMC114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC114 will be administered as oral tablets (75 milligram \[mg\] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
Trial: NCT04740424
Drug: FS222
RxNorm normalized name: Fentanyl Sublingual Spray 222 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.
Trial: NCT01396655
Drug: docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
Trial: NCT01218035
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. All infusions will be given 100 ml in volume and infused over a period of 15 minutes with a pre- and post-infusion flush with normal saline.
Trial: NCT02077621
Drug: PG2
RxNorm normalized name: Fossaoprin SPG2 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for Injection, 500 mg PG2/500 ml normal saline
Trial: NCT02077621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL normal saline
Trial: NCT02345382
Drug: Atuveciclib, BAY1143572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
Trial: NCT02119052
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00709137
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
Trial: NCT00709137
Drug: amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
Trial: NCT02494505
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00536835
Drug: GSK461364
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
Trial: NCT02955693
Drug: LAS41008 120 mg / Fumaderm® 120 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
Trial: NCT01898598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo to vismodegib for 12 weeks.
Trial: NCT01875237
Drug: Mini Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2 by vein on Days +1, +3, +6.
Trial: NCT01875237
Drug: AP1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade \> 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
Trial: NCT03782662
Drug: Placebo for RV521
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for RV521 capsules
Trial: NCT01134991
Drug: Topical Minocycline Foam FXFM244
RxNorm normalized name: minocycline Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
Trial: NCT00905073
Drug: cyclosporin and methotrexate
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
Trial: NCT04150393
Drug: MaaT033 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT01436448
Drug: Probiotics Lactobacillus Rhamnosus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
Trial: NCT04294472
Drug: MAU868
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAU868 is a human monoclonal antibody (IgG1) that binds the viral capsid protein, VP1, that is responsible for binding to the surface of host cells
Trial: NCT01763658
Drug: Antox tablets(Mepaco)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: effect of antioxidant on disease outcome
Trial: NCT01169038
Drug: levaquin; ethambutol; rifampin and azithromycin.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~\*\*Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. \*\*We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway.
Trial: NCT01573819
Drug: GSK356278
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
Trial: NCT01573819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
Trial: NCT03077750
Drug: VBP-245 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application BID
Trial: NCT03077750
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Control With No Active Pharmaceutical Ingredients
Trial: NCT01705483
Drug: ASP9853
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00446290
Drug: Docetaxel, Capecitabine and Oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01129648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered daily for 21 days
Trial: NCT01251393
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
Trial: NCT01129648
Drug: BCX4208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered daily for 21 days.
Trial: NCT04650750
Drug: Xiao-Feng-San+Shian-Fang-Hwa-Ming-Yiin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiao-Feng-San is a common Chinese herbal preparation, composed of 13 herbs, which is used to treat patients with dermatitis. The component of Xiao-Feng-San has immunomodulatory activity. Shian Fang Hwa Ming Yiin is another common Chinese herbal preparation, composed of 12 herbs, which is used to treat patients with carbuncles and acne. The component of Shian Fang Hwa Ming Yiin has anti-inflammation and anti-microbial effect.
Trial: NCT04650750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar placebo 4g twice a day for two months
Trial: NCT01273480
Drug: Sequence 1
RxNorm normalized name: Antihemophilic Factor (Recombinant) Porcine Sequence 1 U Intravenous Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
Trial: NCT01094262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
Trial: NCT02142543
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02710214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of placebo for 8 weeks
Trial: NCT03710707
Drug: DNL201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT03710707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT03091868
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules. Oral administration.
Trial: NCT02466087
Drug: Mg Cl
RxNorm normalized name: Saizen 8.8mg Click.Easy Cartridge Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four supplements a day for 6 weeks.
Trial: NCT05475431
Drug: The triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.
Trial: NCT01129648
Drug: BCX4208
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adminstered daily for 21 days
Trial: NCT00528658
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg tid
Trial: NCT03129061
Drug: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.~* Anti PD-1 per standard of care~* Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.~* \[18F\]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose.
Trial: NCT03129061
Drug: [18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Baseline: Blood sampling, tumor biopsy, \[18F\]F-AraG PET/CT scan within two weeks prior to treatment.~* Anti PD-1, single dose~* Blood sampling, tumor biopsy and \[18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection.
Trial: NCT00528658
Drug: Paracetamol Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equivalent to 1g qid
Trial: NCT00528658
Drug: Ibuprofen placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent to 400mg tid
Trial: NCT02377349
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
Trial: NCT01516554
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily
Trial: NCT00429299
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600mg/sqm iv day 1 q21 days for four coursess
Trial: NCT00429299
Drug: epidoxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg/sqm iv day 1 q21 days for four courses
Trial: NCT00429299
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600mg/sqm day 1 q21 days for four courses
Trial: NCT02643784
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.
Trial: NCT01332968
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
Trial: NCT01332968
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m\^2 IV will be administered on Day 1 of each cycle during induction period.
Trial: NCT01963260
Drug: MK-8723
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
Trial: NCT01963260
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
Trial: NCT00248989
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 ml of placebo cream applied on the skin twice daily.
Trial: NCT00466531
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00372996
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
Trial: NCT00000317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00004860
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03618108
Drug: Doxycycline Capsule
RxNorm normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline capsule
Trial: NCT03618108
Drug: Azithromycin Capsule
RxNorm normalized name: Azithromycin Capsules
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin capsule
Trial: NCT03618108
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule identical in size and form to doxycycline
Trial: NCT04136067
Drug: NNC0268-0965
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One daily dose of 1.5, 4.0 or 6.0 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
Trial: NCT03618108
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule identical in size and form to azithromcyin
Trial: NCT03618108
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule identical in size and form to rifabutin
Trial: NCT02670785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
Trial: NCT02661022
Drug: SL-401 7 µg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SL-401 7 µg/kg/day in combination with pom/dex
Trial: NCT02661022
Drug: SL-401 9 µg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SL-401 9 µg/kg/day in combination with pom/dex
Trial: NCT00001239
Drug: FLAC with GM-CSF
RxNorm normalized name: Flac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02884986
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp \& Dohme) one hour prior to spinal anaesthesia induction
Trial: NCT02884986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120mg of placebo
Trial: NCT00830167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
Trial: NCT01985724
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
Trial: NCT01985724
Drug: 5-fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
Trial: NCT00003350
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00860925
Drug: ASA Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.